Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...

Now that doctors are prescribing anti-amyloid therapies for Alzheimer’s disease, scientists have begun to focus their energy on the other pathological hallmark of AD, neurofibrillary tangles. While ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it can slow the disease’s progression - were always a long-shot, although they had ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...